Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 39
- Registration Number
- NCT00772915
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection
- Conditions
- Macular Degeneration
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Lahey Clinic
- Target Recruit Count
- 28
- Registration Number
- NCT00769392
- Locations
- 🇺🇸
Lahey Clinic Arlington, Arlington, Massachusetts, United States
🇺🇸Lahey Clinic Northshore, Peabody, Massachusetts, United States
🇺🇸Lahey Clinic, Inc., Burlington, Massachusetts, United States
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT00765245
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Nordic MDS Group
- Target Recruit Count
- 28
- Registration Number
- NCT00761449
- Locations
- 🇩🇰
Department of Hematology, Aalborg Hospital, Aalborg, Denmark
🇩🇰Department of Hematology, Herlev Hospital, Herlev, Denmark
🇩🇰Department of Hematology, Rigshospitalet, Copenhagen, Denmark
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00759603
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 27
- Registration Number
- NCT00751296
- Locations
- 🇨🇦
University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS
- Conditions
- Leukemia, Myelomonocytic, ChronicAngiogenesisMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 20
- Registration Number
- NCT00744536
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Odette Cancer Center, Toronto, Ontario, Canada
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
- Conditions
- Hematologic Cancer
- Interventions
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 101
- Registration Number
- NCT00742560
Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- First Posted Date
- 2008-08-21
- Last Posted Date
- 2013-08-30
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 45
- Registration Number
- NCT00738829
- Locations
- 🇦🇹
Universitaetsklinik f. Innere Medizin III, Salzburg, Austria
🇦🇹Klinikum Wels-Grieskirchen GmbH, Wels, Austria
🇦🇹Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie, Innsbruck, Tirol, Austria
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial
- First Posted Date
- 2008-08-19
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 134
- Registration Number
- NCT00737529
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Tower Cancer Research Foundation, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.